Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Malignant Melanoma

Free Subscription 29.06.2020 1 Cancer 1 Int J Cancer 1 J Am Acad Dermatol 1 J Immunother 2 J Surg Oncol 3 Melanoma Res 1 Nat Med 1 Oncogene 2 Ophthalmol Retina 1 Ophthalmology 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Cancer

1. PRINTZ C
   Research notes largest yearly decline in melanoma deaths.
   Cancer. 2020;126:3173.
   PubMed        
   
   

   
   Int J Cancer

2. VAN ZEIJL MCT, Ismail RK, de Wreede LC, van den Eertwegh AJM, et al
   Real-world outcomes of advanced melanoma patients not represented in phase III trials.
   Int J Cancer. 2020 Jun 19. doi: 10.1002/ijc.33162.
   PubMed         Abstract available
   
   

   
   J Am Acad Dermatol

3. SHAH PV, Choi JN, Fiessinger L, Nardone B, et al
   Utilization of immunotherapy among stage 4 melanoma patients: an analysis of the National Cancer Database from 2012-2016.
   J Am Acad Dermatol. 2020 Jun 14. pii: S0190-9622(20)31092.
   PubMed        
   
   

   
   J Immunother

4. GKOUFA A, Gogas H, Diamantopoulos PT, Ziogas DC, et al
   Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature.
   J Immunother. 2020 Jun 16. doi: 10.1097/CJI.0000000000000326.
   PubMed         Abstract available
   
   

   
   J Surg Oncol

5. DELMAN KA
   Minimally invasive inguinal lymphadenectomy.
   J Surg Oncol. 2020;122:96-98.
   PubMed         Abstract available
   
   
6. CARR MJ, Sun J, Zager JS
   Isolated limb infusion: Institutional protocol and implementation.
   J Surg Oncol. 2020;122:99-105.
   PubMed         Abstract available
   
   

   
   Melanoma Res

7. TAS F, Erturk K
   Paradox in melanoma: more patients fewer publications.
   Melanoma Res. 2020 Jun 23. doi: 10.1097/CMR.0000000000000684.
   PubMed         Abstract available
   
   
8. ZANELLA A, Doussot A, Puzenat E, Aubin F, et al
   MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted?
   Melanoma Res. 2020 Jun 23. doi: 10.1097/CMR.0000000000000677.
   PubMed         Abstract available
   
   
9. HADFIELD MJ, Helsing R, Grant-Kels JM
   Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapies.
   Melanoma Res. 2020 Jun 23. doi: 10.1097/CMR.0000000000000679.
   PubMed         Abstract available
   
   

   
   Nat Med

10. LIU D, Schilling B, Liu D, Sucker A, et al
    Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
    Nat Med. 2020 Jun 19. pii: 10.1038/s41591-020-0975.
    PubMed         Abstract available
    
    

    
    Oncogene

11. ZHANG X, Yang L, Szeto P, Abali GK, et al
    The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis.
    Oncogene. 2020 Jun 19. pii: 10.1038/s41388-020-1362.
    PubMed         Abstract available
    
    

    
    Ophthalmol Retina

12. LIU TYA, Zhu H, Chen H, Arevalo JF, et al
    Gene Expression Profile Prediction in Uveal Melanoma Using Deep Learning: a Pilot Study for Development of an Alternative Survival Prediction Tool.
    Ophthalmol Retina. 2020 Jun 18. pii: S2468-6530(20)30251.
    PubMed         Abstract available
    
    
13. MURRAY TG, Latiff A, Villegas VM, Gold AS, et al
    Aflibercept for Radiation Maculopathy Study: A Prospective, Randomized Clinical Study.
    Ophthalmol Retina. 2019;3:561-566.
    PubMed         Abstract available
    
    

    
    Ophthalmology

14. ESPENSEN CA, Kiilgaard JF, Appelt AL, Fog LS, et al
    Dose-response and normal tissue complication probabilities after proton therapy for choroidal melanomas.
    Ophthalmology. 2020 Jun 20. pii: S0161-6420(20)30572.
    PubMed         Abstract available
    
    

    
    PLoS One

15. GRZYWA TM, Klicka K, Paskal W, Dudkiewicz J, et al
    miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.
    PLoS One. 2020;15:e0234707.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: